Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Contusugene ladenovec (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors Shenzhen SiBiono GeneTech
- 11 Feb 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 22 May 2009 New trial record